Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Parke-Davis discusses development of potent, irreversible EGF receptor TK inhibitors

June 30, 1998

Oxidized phenolic compounds with an unexpected mechanism of action

June 30, 1998

U.S. patent licensed to Avax Technologies issued for anticancer compounds

June 30, 1998

Various schedules and doses of DMDC explored in phase I

June 29, 1998

Pyrazoloacridine evaluated in patients with pancreatic and hepatobiliary cancer

June 29, 1998

Preclinical studies with doranidazole summarized

June 29, 1998

Modulators of drug/multidrug resistance from Lilly

June 29, 1998

Tricyclic antitumor compounds developed at Schering-Plough

June 29, 1998

New class of FPTase inhibitors discovered at Merck & Co.

June 29, 1998

Melphalan derivative pinpointed for further study

June 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...